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ABSTRACT
Objectives: To assess the incidence and economic implica-
tions of loss of treatment response among patients with
Crohn’s disease (CD) treated with inﬂiximab maintenance
therapy.
Methods: This was a retrospective observational study of
inﬂiximab response and costs among patients with CD using
a large health-care claims database. Patients with CD receiv-
ing inﬂiximab maintenance therapy with an initial response
were selected from the Integrated Healthcare Informa-
tion Services claims database (1999–2005). Patients’ claim
histories were used to identify patterns of response to inﬂix-
imab treatment. Incidence of loss of response was estimated
using Kaplan–Meier method. Annual total health-care
and CD-related costs were estimated and adjusted for in-
ﬂation to 2005 US dollars. Generalized linear model was
used to assess the impact of loss of response on treatment
costs.
Results: The study sample included 262 patients with CD
with an initial response to inﬂiximab therapy. Within
24 months of therapy initiation, 77% of patients lost treat-
ment response. Upward dose adjustment, a new drug therapy
for CD, and CD-related emergency room or inpatient visits
were the three most common indicators of loss of response.
Both annual total and CD-related health-care costs for
patients who lost treatment response during the ﬁrst year
were found to be approximately one-third higher than for
those who did not lose response.
Conclusions: The majority of patients who had initial
responses to inﬂiximab maintenance treatment subsequently
lost response within 2 years. Loss of response was associated
with a signiﬁcant increase in total health-care and CD-related
costs.
Keywords: Crohn’s disease, health economics, inﬂiximab,
treatment failure.
Introduction
Crohn’s disease (CD) is a chronic, relapsing inﬂamma-
tory bowel disease of an unknown etiology. CD affects
approximately 144 to 198 people per 100,000 in
North America [1]. Its recurrent symptoms and com-
plications can signiﬁcantly impact patients’ physical
and emotional well-being, as well as prevent their
maintenance of gainful employment over the course of
a lifetime [2]. Therefore, CD imposes a signiﬁcant
economic burden on patients and health-care systems.
The direct medical cost of treating CD in the United
States was estimated to be more than $1.7 billion in
1996 [3,4], with surgery and hospitalizations account-
ing for more than half of that total [5].
There are no curative medical or surgical interven-
tions for CD. Clinical management has traditionally
focused on treatment of acute episodes and mainte-
nance of remission [6]. With varying degrees of
safety and effectiveness, several types of drugs are
commonly used for these purposes, including
systemic corticosteroids, immunomodulators (i.e.,
azathioprine, 6-mercaptopurine), broad-based immu-
nosuppressants (e.g., methotrexate), aminosalicylates,
antibiotics, and biologic agents [7].
Inﬂiximab is a chimeric (i.e., human-murine) mono-
clonal antibody that binds with the proinﬂammatory
cytokine tumor necrosis factor with a substantial
degree of speciﬁcity and afﬁnity, thereby neutralizing
the bioactivities in the disease cascade of CD [8]. In
the United States, inﬂiximab was ﬁrst approved by the
Food and Drug Administration (FDA) on August 24,
1998, for the treatment of moderately to severely
active CD and was later approved for maintenance
therapy on June 28, 2002 [9].
According to the FDA-approved product label,
inﬂiximab was approved for “reducing the signs and
symptoms and inducing and maintaining clinical
remission in adult and pediatric patients with moder-
ately to severely active Crohn’s disease who have had
inadequate responses to conventional therapy” [9]. In
addition to CD, inﬂiximab was also approved for
rheumatoid arthritis, ankylosing spondylitis, psoriatic
arthritis, and ulcerative colitis [9].
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The recommended dose of inﬂiximab for CD is
5 mg/kg given as an intravenous induction regimen at
Weeks 0, 2, and 6 followed by amaintenance regimen of
5 mg/kg every 8 weeks thereafter (i.e., the fourth dose is
administered at Week 14) for the treatment of adults
with moderately to severely active or ﬁstulizing CD.
For adult patients who respond and then lose their
response, consideration may be given to treatment with
10 mg/kg. Clinical trials have demonstrated the efﬁcacy
and safety of inﬂiximab in inducing remission in some
patients with CD [10]. Studies have also demonstrated
that patients receiving inﬂiximab may form antibodies
to inﬂiximab [11,12], which is “associated with an
increased risk of infusion reactions and a reduced dura-
tion of response to treatment” [13]. It has been demon-
strated that the presence of antibodies to inﬂiximab in
concentrations greater than 8.0 mg/ml before infusion
was predictive of a shorter duration of treatment
response and a higher risk of infusion reactions [13].
Compared to other conventional drug therapies cur-
rently available for CD (e.g., systemic corticosteroids,
5-aminosalicylates, and immunomodulators), inﬂix-
imab had a higher acquisition cost of $542.40 per
100-mg vial in mid-2006 based on Average Sale Price
plus 6% [14,15]. Based on the assumption of a stable
dosage over time, studies have found that the annual
cost of inﬂiximab maintenance therapy can range from
approximately US $16,422 to $45,944 per patient per
year [16,17]. Some economic studies have evaluated
the relative cost-effectiveness of inﬂiximab therapy
compared to other conventional therapies. Results are
mixed and appear to depend on the treatment popula-
tion, as well as the particular modeling methods and
assumptions used. Inﬂiximab therapy was shown to be
marginally cost-effective to not cost-effective compared
with standard care [15,18]. Most available economic
evaluations of inﬂiximab use modeling approach and
therefore are sensitive to model assumptions [15,18].
Although clinical results of inﬂiximab therapy are
readily available, primary economic proﬁles of CD
with inﬂiximab therapy are scarce [19]. Furthermore,
economic assessments of inﬂiximab often neglect the
consequences of upward dose adjustment, clinical
safety monitoring, and adverse reactions on infusion-
related expenses and costs. According to A Crohn’s
Disease Clinical Trial Evaluating Inﬂiximab in a New
Long-Term Treatment Regimen (ACCENT I), more
than half of patients in the 5 mg/kg inﬂiximab main-
tenance group lost response by 1 year [20]. In particu-
lar, despite a noted substantial incidence of loss of
response to inﬂiximab even with maintenance therapy,
the corresponding economic consequences of loss of
response have not been fully analyzed. This omission is
more remarkable given that economic studies have
found inﬂiximab to be marginally cost-effective based
on long-term clinical outcomes [18,21]. As response
is lost, the health-care costs of patients with CD may
increase. The lack of understanding and illumination
of the cost consequence of loss of response may have
led to a substantially biased estimate of the costs of
inﬂiximab therapy. To address this issue, this study
examined the incidence and economic impact of loss of
treatment response among patients with CD treated
with inﬂiximab maintenance therapy.
Methods
Study Design
This study followed patients with CD with initial
responses to inﬂiximab maintenance therapy and
investigated long-term treatment responses and the
costs associated with the loss of response.
Patients in this study were identiﬁed from the
Integrated Healthcare Information Services claims
database (1999–2005). This US administrative claims
database contains information for more than 13
million enrollees from more than 35 health plans. It
contains information on patients’ health plan eligibil-
ities and enrollment records, as well as medical and
outpatient pharmacy claims.
Patients were included in this study if they met all six
of the following criteria: 1) the patient had at least two
independent CD diagnoses (based on the International
Classiﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation [ICD-9-CM] code 555.xx); 2) all of the
patient’s inﬂiximab infusion medical claims were asso-
ciated with a diagnosis of CD; 3) the patient’s ﬁrst
inﬂiximab infusion date for maintenance therapy (i.e.,
index date) was between July 1999 and June 2004;
4) the patient was continuously eligible for at least
6 months before and 12 months after the index date;
5) the patient was on inﬂiximab maintenance therapy
(deﬁned as a minimum of four consecutive infusions
with no between-infusion intervals >12 weeks [inﬂix-
imab infusion records were identiﬁed from medical
claims with Healthcare Common Procedure Coding
System (HCPCS) code J1745, inﬂiximab 10 mg]); and
6) the patient did not have an outpatient pharmacy
prescription of inﬂiximab. The last criterion was
applied because inﬂiximab prescriptions ﬁlled at a phar-
macy are rare—in the Integrated Healthcare Informa-
tion Services database, only 2.8% (213 out of 7740) of
inﬂiximab users have any pharmacy prescription of
inﬂiximab. Also, pharmacy prescriptions of inﬂiximab
are excluded because pharmacy databases do not
provide information on the disease indication for which
the prescription is written. Therefore, it is impossible to
determine whether an outpatient pharmacy prescrip-
tion of inﬂiximab is used to treat CD. Furthermore,
pharmacy prescriptions of inﬂiximab are usually ﬁlled
at a ﬁxed interval (usually every 3 months); this will not
provide sufﬁcient information to determine the dose
used per infusion during this period and the frequencies
of infusion during this period.
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Patients who did not have an initial response were
excluded from the study. To qualify as having an initial
response, patients must not have had any of the follow-
ing ﬁve indicators of lack of improvement from the ﬁrst
to the fourth infusion dates: 1) a CD-related surgery,
deﬁned as all surgical procedures related to the bowel,
rectum, and anus as identiﬁed by CPT codes; 2) a
diagnosis of a new ﬁstula that did not appear in the
6-month preindex period; 3) an emergency room visit
or a hospitalization with a diagnosis of CD; 4) an
initiation of a new CD drug therapy that had not
been used previously (including a biologic other than
inﬂiximab, aminosalicylates, immunomodulators,
methotrexate, corticosteroids, or metronidazole and
ﬂuoroquinolone family antibiotics); and 5) an occur-
rence of upward dose adjustment of inﬂiximab, deﬁned
as any increase in dose amount versus the second infu-
sion dose, and/or an increase in dosing frequency
(<7 weeks interval twice during therapy), beginning
with the third infusion as noted byOllendorf et al. [22].
A lack of response to inﬂiximab treatment would
almost invariably lead to one or more of these ﬁve
indicators being observed. If patients do not respond
to inﬂiximab therapy, they frequently develop a new
ﬁstula or require urgent care, invasive procedures, a
new therapy, or dosage increases of inﬂiximab. To this
point, inﬂiximab dosage increases are recommended
for loss of response according to the prescribing infor-
mation in the product label [20]. Similar indicators for
loss of response to inﬂiximab therapy were used in the
Gauging Adalimumab Efﬁcacy in Inﬂiximab Nonre-
sponders study, which was a randomized controlled
trial based on an FDA-approved study design [23].
Again, only patients with none of the ﬁve indicators
before the fourth infusion date were considered to
have an initial response and were included in this
study. The choice of requiring the fourth infusion is
consistent with a recent CD clinical study that evalu-
ated inﬂiximab as part of a long-term treatment
regimen trial (ACCENT II) that evaluated loss of
response (where initial response was evaluated at
Weeks 10 and 14) [15].
For cost analysis, the study sample was restricted to
patients with health insurance eligibility during the
period starting from 6 months before the index date
(baseline) to 12 months after the index date (Fig. 1).
The 6-month baseline period allowed for the character-
ization of patients’ baseline medical and cost proﬁles
and the 12-month period following index date were
used to deﬁne treatment costs associated with loss-of-
response status. To study loss of treatment response
rate, patients were followed until any of the ﬁve indi-
cators occurred or until the end of data availability (i.e.,
June 30, 2005, or end of insurance eligibility), which-
ever occurred ﬁrst. The time to loss of response was
deﬁned as the time from the index date to the earliest
occurrence of any of the ﬁve indicator events.
Analytical Methods
Demographics and baseline medical proﬁles for the
patients who experienced a loss of treatment response
within 1 year were compared to those of patients who
did not experience a loss of response. Chi-square sta-
tistics were used to test the statistical signiﬁcance for
discrete variables between the two groups, and Wil-
coxon rank tests were used to test changes in continu-
ous variables.
Because patients may not have had 24 months of
insurance eligibility following their index dates, the
Kaplan–Meier survival method was used to estimate
the 2-year rate of loss of treatment response. In addi-
tion to the overall loss-of-response rate, the occurrence
rate for each of the ﬁve indicator events was estimated
individually.
To study the economic implications of loss of
response comprehensively, both total and CD-related
medical costs during the year following the index date
were estimated. Reported costs were reimbursement
amounts, and professional service rates were standard-
ized by major service types. Total health-care costs
were all medical and pharmacy claims within this
1-year period. Medical services claims encompassed
inpatient, outpatient, and emergency room visits, as
well as services provided in other locations (e.g., home,
ambulatory surgical centers, skilled nursing facilities,
nursing homes, ambulances, rehabilitation facilities,
and independent laboratories). CD-related costs were
costs for medical claims with the presence of a CD
diagnosis (ICD-9-CM code: 555.xx) and CD-related
medication costs. CD-related costs also included inﬂix-
imab infusion claims and all medical claims that
occurred on the infusion date (to capture the total cost
of infusion-related services). All costs were inﬂation-
adjusted to 2005 US dollars using the medical compo-
nent of the US Consumer Price Indexes. Wilcoxon rank
tests were used to test for differences in costs between
patients who experienced a loss of response and
patients who did not. In addition to comparing
patients with loss of response to those without loss of
response, we also examined the total medical costs and
CD-related costs by each of the ﬁve indicators for lack
of improvement descriptively.
A multivariate analysis was also conducted to
examine the association between loss of response in
total and CD-related health-care costs. Speciﬁcally, a
generalized linear model with a log link function and
gamma distribution was used. The model was able to
control for confounding factors, including patient
demographics, types of insurance, presence of comor-
bidities (e.g., rheumatoid arthritis, depression, hyper-
tension, cardiovascular diseases, gastroesophageal
reﬂux disease [GERD], chronic obstructive pulmonary
disease), venue of infusion (e.g., outpatient, physician
ofﬁce, inpatient, emergency room), prior medications
used, and prior resource utilizations.
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Results
A total of 378 patients with CD were treated with
inﬂiximab maintenance therapy. Of these, 116 patients
had at least one of the ﬁve indicators of lack of
improvement before the fourth infusion date. These
116 patients were considered to be lacking initial
response and therefore were excluded from the study.
The remaining 262 patients comprised the ﬁnal study
sample. By the end of 12 months following the ﬁrst
inﬂiximab infusion, 141 (54%) patients experienced
loss of treatment response.
Patient Demographics
The overall sample population had a mean age of
38.6 years and half were male (Table 1). The majority
of patients (64.5%) received their index infusions in
physicians’ ofﬁces, and most of the remaining patients
(28.6%) received their index infusions in hospital out-
patient settings. Patients who lost response within
1 year generally shared similar demographic and
comorbidity proﬁles at baseline to those who did not.
At baseline, patients who did not lose treatment
response within the ﬁrst year were more likely to have
had rheumatoid arthritis (7.4% vs. 2.1%, P = 0.04)
and higher use of immunomodulators (i.e., azathio-
prine, 6-mercaptopurine) (55.4% vs. 41.1%, P = 0.02)
than those who lost response within the ﬁrst year.
Corticosteroids were the most common prior/
concomitant medication, used by 65% (n = 171) of
the study sample before the inﬂiximab maintenance
therapy, followed by aminosalicylates, by 60%
(n = 158) of patients at baseline.
Incidence Rates of Loss of Response
The overall 2-year loss of inﬂiximab maintenance
treatment response rate for the study sample was 77%
(Fig. 2a), based on Kaplan–Meier estimates. Inﬂiximab
dosage escalation, initiation of new drugs, and
CD-related urgent care (i.e., emergency room, inpa-
Patients with at least one infusion of infliximab 
(Identified by HCPCS code J1745) 
 
N = 7740 
First infusion of infliximab between 07/1999 and 06/2004 
 
N = 6375 (82.4%) 
 
Diagnosis of Crohn?s disease (CD) 
(Identified by ICD-9-CM code 555.xx) 
 
N = 2834 (36.6%) 
At least two diagnoses of CD 
N = 2470 (31.9%) 
No pharmacy prescription of infliximab 
N = 2445 (31.6%) 
6 months continuous eligibility prior to and 12 months following index date 
(Index date defined as first infusion date of infliximab) 
 
N = 1145 (14.8%) 
All infliximab infusions were associated with a diagnosis of CD 
N = 1024 (13.2%) 
Patients on infliximab maintenance therapy  
(Defined as a minimum of 4 consecutive infusions with no between-infusion intervals >12 weeks) 
 
N = 378 (4.9 %) 
Infliximab maintenance therapy patients with initial response 
N = 262 (3.4%) 
Figure 1 Patient sample selection ﬂowchart
for the study. A total of 7740 patients were
identiﬁed with at least one infusion of inﬂix-
imab. The ﬁnal sample for this study was 262.
HCPCS, Healthcare Common Procedure
Coding System; ICD-9-CM, International Clas-
siﬁcation of Diseases, Ninth Revision, Clinical
Modiﬁcation.
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tient visits) were the most common indicators for loss
of treatment response (Fig. 2b and Table 2). After
2 years, 44% of patients with CD experienced dosage
escalations and 44% initiated new drug therapies. The
rate of CD-related emergency room visits or inpatient
hospitalizations after 2 years was 32%. The rate of
CD-related surgeries was 20% and the rate of a new
ﬁstula diagnosis was 12% (Table 2).
Cost of Treatment
During the 6-month baseline period, patients who later
lost treatment response and those who did not
incurred similar total treatment costs (US $10,385
vs. $10,589, P > 0.05) (Fig. 3). During the 12-month
follow-up period, those who did not experience loss of
treatment response incurred $24,532 in total costs,
on average, whereas those who did experience loss
of response incurred 36% greater mean total costs
($33,289). The cost difference ($8756) between the
two groups was statistically signiﬁcant (P < 0.001).
Similarly, patients who did not experience loss of
response with inﬂiximab treatment within 1 year
incurred $19,506 in CD-related medical and pharmacy
costs compared to $27,250, or 40% greater
CD-related costs for patients who experienced loss
of treatment response. The $7744 difference was also
statistically signiﬁcant (P < 0.001). Based on these
results, 88% of the total cost difference ($8756) was
CD related. Descriptive comparison results of total
medical costs and CD-related costs by each of the ﬁve
indicators for lack of improvement are shown in
Table 3. Total treatment costs and CD-related costs
were generally higher among patients who had such
indicators than those who did not have them. The
costs were signiﬁcantly higher among patients who
had experienced a CD-related surgery, CD-related
emergency department visit or hospitalization, or a
new CD-related drug therapy than otherwise. In par-
ticular, patients with an emergency department visit
or hospitalization had total and CD-related costs
Table 1 Patient demographic characteristics at baseline period
Characteristic
Total
(N = 262)
Experienced no loss
of response
(n = 121)
Experienced loss of response
(n = 141) P-value
Age at index year, mean (SD) 38.55 (13.88) 38.32 (14.04) 38.74 (13.79) 0.6138
Age at index year, range 10–74 10–74 11–68
Male sex, n (%) 130 (49.6) 60 (49.6) 70 (49.6) 0.9925
Year of index date, n (%) 0.7271
2000 8 (3.1) 4 (3.3) 4 (2.8)
2001 18 (6.9) 10 (8.3) 8 (5.7)
2002 65 (24.8) 28 (23.1) 37 (26.2)
2003 111 (42.4) 48 (39.7) 63 (44.7)
2004 60 (22.9) 31 (25.6) 29 (20.6)
Venue of infusion, n (%) 0.6289
Home 17 (6.5) 7 (5.8) 10 (7.1)
Hospital outpatient 75 (28.6) 38 (31.4) 37 (26.2)
Other 1 (0.4) 0 (0.0) 1 (0.7)
Physician’s ofﬁce 169 (64.5) 76 (62.8) 93 (66.0)
Insurance type, n (%) 0.8148
HMO 64 (24.4) 29 (24.0) 35 (24.8)
Other 16 (6.1) 8 (6.6) 8 (5.7)
POS 40 (15.3) 21 (17.4) 19 (13.5)
PPO 142 (54.2) 63 (52.1) 79 (56.0)
Comorbidities, n (%)
Rheumatoid arthritis 12 (4.6) 9 (7.4) 3 (2.1) 0.0404
MDD 10 (3.8) 5 (4.1) 5 (3.5) 0.8050
Cardiovascular disease 14 (5.3) 4 (3.3) 10 (7.1) 0.1743
Hypertension 23 (8.8) 7 (5.8) 16 (11.3) 0.1127
GERD 21 (8.0) 7 (6.0) 14 (10.0) 0.2181
Hyperlipidemia 14 (5.3) 7 (5.8) 7 (5.0) 0.7684
COPD 20 (7.6) 10 (8.3) 10 (7.1) 0.7217
Deyo Charlson Comorbidity
Index
0.23–0.73 0.31–0.96 0.16–0.46 0.2034
Presence of any ﬁstula during
the baseline period, n (%)
36 (13.7) 19 (15.7) 17 (12.1) 0.3928
Medications use during the baseline
period, n (%)
Aminosalicylates 158 (60.3) 70 (57.9) 88 (62.4) 0.4520
Corticosteroids 171 (65.3) 79 (65.3) 92 (65.2) 0.9945
Antibiotics 117 (44.7) 57 (47.1) 60 (42.6) 0.4598
Immunomodulators* 125 (47.7) 67 (55.4) 58 (41.1) 0.0214
Methotrexate 16 (6.1) 6 (5.0) 10 (7.1) 0.4721
*Immunomodulators include azathioprine and 6-mercaptopurine.
COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reﬂux disease; HMO, health maintenance organization; MDD, major depressive disorder; POS, point of
service; PPO, preferred provider organization; SD, standard deviation.
824 Wu et al.
($48,128, $39,099) approximately twice as much as
those who did not experience urgent care ($25,843,
$20,895; P < 0.0001 for both). Nevertheless, for most
of the comparisons, the loss of treatment response
group by individual indicator had small sample size.
Regression results showed that factors inﬂuencing
total health-care costs for patients with CD, as well as
health-care costs incurred before the maintenance
therapy, included loss of response to inﬂiximab main-
tenance treatment, age, and comorbidities of cardio-
vascular disease and GERD (Table 4). Loss of response
to treatment was a signiﬁcant driver of total health-
care costs. For the 1-year total health-care costs, the
regression coefﬁcient from the generalized linear model
with log link function for the loss of response was
0.2545 (P < 0.001), which translated to 29% greater
total health-care costs for those patients with CD
who experienced loss of response within 1 year of
Table 2 Two-year loss-of-response rate for patients with CD
receiving inﬂiximab maintenance therapy with initial response
(N = 262)
Lack of improvement indicator N %
Experienced upward dose adjustment of inﬂiximab* 104 44.7
Received new medication therapy for CD† 98 44.3
Received CD-related urgent care
(emergency department, inpatient)‡
72 31.7
Received CD-related surgery 46 19.7
Diagnosed with new ﬁstula§ 27 12.3
Loss of response by any one of the above 187 77.0
*Upward dose adjustment was deﬁned as dose increase after the third infusion, or
two or more shortened intervals (<7 weeks).
†Classes of drugs for treating CD that have not been received during the 6 months
before inﬂiximab therapy: a biologic other than inﬂiximab, aminosalicylates, immuno-
modulators (azathioprine, 6-mercaptopurine), methotrexate, corticosteroids, or met-
ronidazole and ﬂuoroquinolone family antibiotics.
‡Emergency room visit or inpatient hospitalization claims with CD as a diagnosis code
(ICD-9-CM: 555.xx).
§ICD-9-CM diagnosis codes of ﬁstula includes 565.1, 569.81, 998.5, 599.1, and 619.
CD, Crohn’s disease; ICD-9-CM, International Classiﬁcation of Diseases, Ninth Revi-
sion, Clinical Modiﬁcation.
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Figure 2 (a) Rate of loss of response over time for patients with Crohn’s
disease (CD) receiving inﬂiximab maintenance therapy. Seventy-seven
percent of patients had lost treatment response within 24 months of
initiation of therapy. (b) Rate of loss of response by each of ﬁve indicators.
Inﬂiximab upward dose adjustment, initiation of new drugs, and
CD-related urgent care were the most common indicators for loss of
treatment response.
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Figure 3 Mean baseline costs, annual total
health-care costs, and Crohn’s disease (CD)-
related costs by loss-of-response status for 262
study patients.All values were inﬂation-adjusted
to 2005 US dollars using the medical compo-
nent of the US Consumer Price Indexes.
Wilcoxon rank tests were used to test for
differences in costs between patients who
experienced a loss of response and patients
who did not. *P < 0.01.
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inﬂiximab maintenance therapy versus those who
did not. Similarly, loss of response to maintenance
treatment was also a statistically signiﬁcant factor
for CD-related health-care costs for these patients
(Table 5). It was associated with 29.3% greater
CD-related costs (P < 0.001, coefﬁcient = 0.2571).
Conclusions
This study ﬁlls a gap in the inﬂiximab treatment/health
economics literature [24] by investigating two issues:
1) the incidence of loss of treatment response to inﬂix-
imab maintenance treatment; and 2) the cost implica-
tions of this lost response. Although inﬂiximab has
emerged as a common treatment for moderate to
severe CD, its long-term medical and economic ben-
eﬁts as maintenance therapy had remained unclear.
In this analysis, 77% of patients had lost treatment
response to inﬂiximab within 24 months. The three
most commonly seen lack-of-improvement indicators
were inﬂiximab dosage escalation (44%), new medi-
cation therapy for CD (44%), and CD-related urgent
care (i.e., emergency room, inpatient; 32%). This is
especially signiﬁcant in that surgery and hospitaliza-
tion typically constitute most of the total treatment
costs for patients with CD [5]. In addition, this study is
likely to have underestimated the true extent of dosage
escalation among patients treated with inﬂiximab
because the 44% point estimate excludes patients who
experienced early-dosage escalation before the fourth
infusion.
Comparing the baseline characteristics including
patient demographics, comorbidities, prior drug
therapy, and baseline resource utilization and costs, it
appears that there were few differences between
patients who lost response and those who did not lose
response. The only two variables with signiﬁcant dif-
ferences (rheumatoid arthritis and immunomodula-
tors) between the two groups showed that patients
who lost response might have less severity at baseline.
To further investigate this issue, we also presented the
baseline costs by each indicator as shown in Table 3.
Except for CD-related emergency and hospitalization,
none of the indicators were associated with higher
baseline costs. Therefore, it appears that response to
inﬂiximab was not strongly associated with CD sever-
ity measured at baseline.
Earlier studies of inﬂiximab therapy often underes-
timated the extent of the cost consequences of loss of
treatment response. This study compared the total
annual health-care and CD-related costs between sub-
groups of patients with CD with different treatment
outcomes. Both descriptive and regression analysis
results show that loss of response is associated with a
one-third increase in both total and CD-related costs.
Inﬂiximab is indicated for moderate to severe CD.
The study sample includes patients with CD inTa
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managed care insurance plans that were treated with
inﬂiximab. Therefore, it represents a relatively severe
side of the CD severity spectrum, which should be
considered when interpreting the economic outcomes.
In the absence of the CD activity index (CDAI), the
gold standard for classifying CD severity, data regard-
ing comorbidity, ﬁstula, past drug use, and baseline
resource utilization and costs were used to proﬁle
patient severity and were controlled in the regression
models. Patients with moderate CD and those with
severe CD may have different reasons of initiation of
and response to inﬂiximab therapy. As a limitation of
this claims database study, we could not separate
patients with moderate CD from the patients with
severe CD. Further clinical research with CDAI is
needed to further examine inﬂiximab loss of response
rate and economic outcomes stratiﬁed by baseline
severity of CD.
Another limitation of this study was that it used
claims data to determine patients’ clinical outcomes
versus direct observation of clinical response mea-
surements, which were not available. Rather, ﬁve
proxy indicators of loss of response were used. None-
theless, it is worth noting that the observed loss-of-
response rate after 1 year (54%) is identical to the
loss-of-response rate at Week 54 reported in the
ACCENT I trial for the inﬂiximab maintenance
therapy group [11]. The beneﬁt of using claims data
is that claims allow for the evaluation of loss-of-
response rates over a longer time period (e.g.,
2 years) than was done in clinical trials. These data
reﬂect real-world loss-of-response rates. In addition,
claims data enable a reliable estimation of economic
costs associated with long-term treatment response
with inﬂiximab therapy.
The results of this study indicate that loss of response
was prevalent for US patients with CD who received
inﬂiximab maintenance therapy in a real-world setting.
The economic consequences of loss of response or lack
of sustained response to inﬂiximab maintenance
therapy present a signiﬁcant source of treatment costs
and should be explicitly considered in any economic
evaluation of inﬂiximab treatment of CD.
The authors would like to thank Michael Nissen, ELS, of
Abbott Laboratories for his editorial assistance in the devel-
opment of this manuscript and would like to acknowledge
that they have received his permission to list him here.
Table 4 General linear model for total treatment costs for patients with CD receiving inﬂiximab maintenance therapy with initial
response (N = 262)
Independent variable Coefﬁcient Standard error P-value
Intercept 9.6608 0.1198 <0.0001*
Indicator on whether loss of response was experienced 0.2545 0.0484 <0.0001*
Insurance type
HMO -0.0324 0.0585 0.5794
Other 0.0658 0.1000 0.5109
POS -0.0022 0.0678 0.974
PPO (reference group)
Male sex 0.0241 0.0477 0.6130
Age at index year 0.0045 0.0019 0.0189†
Comorbidities
Rheumatoid arthritis 0.0149 0.1138 0.8957
Major depressive disorder 0.2226 0.1231 0.0706
Cardiovascular diseases 0.5861 0.109 <0.0001*
Hypertension -0.1569 0.0916 0.0867
GERD 0.191 0.0893 0.0326**
Hyperlipidemia 0.0609 0.1162 0.6000
COPD 0.0605 0.0882 0.4930
Medications used during the baseline period
Aminosalicylates 0.0463 0.0477 0.3312
Corticosteroids 0.0915 0.0506 0.0707
Antibiotics -0.0205 0.0503 0.6841
Immunomodulators 0.0037 0.0487 0.9397
Methotrexate 0.1084 0.1007 0.2817
Presence of ﬁstula within baseline period -0.0559 0.0701 0.4247
Number of months of continuous eligibility before index date -0.0013 0.0017 0.4457
Venue of inﬂiximab infusion
Home 0.0790 0.0948 0.4043
Hospital outpatient 0.0624 0.0526 0.2352
Other -0.6444 0.3878 0.0965
Physician’s ofﬁce (reference group)
Maintenance patients who followed label deﬁnition 0.0878 0.052 0.0916
Indicator on 6-month baseline inpatient cost -0.0962 0.0694 0.1658
6-month baseline total cost/1000 0.0102 0.0024 <0.0001*
*P < 0.01; **P < 0.05.
COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reﬂux disease; HMO, health maintenance organization; MDD, major depressive disorder; POS, point of
service; PPO, preferred provider organization.
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